2007-11-27T00:00:00
We read Sophia Christie's article on collective commissioning with interest. Ms Christie clearly takes the view that no patient with a rare disease is worth treating, as drugs developed for such conditions have limited evidence and are very expensive due to high development costs. So much for the NHS being ...
With a HSJ subscription you’ll unlock:
Already a subscriber? Sign into your account here
Part of HSJ Information Ltd. The White Chapel Building, 1st Floor, 10 Whitechapel High Street, London, E1 8QS. Registered in England and Wales. Company registration 2530185
Site powered by Webvision Cloud